Results 11 to 20 of about 133,754 (301)

Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer [PDF]

, 2012
In our previous work we showed that NGAL, a protein involved in the regulation of proliferation and differentiation, is overexpressed in human breast cancer (BC) and predicts poor prognosis.
Arnold, Norbert, Ataseven, Beyhan, Bauer, Maret, Darb-Esfahani, Silvia, Denkert, Carsten Michael, Hamann, Sigrid, Holzhausen, Hans-Jürgen, Jonat, Walter, Khandan, Fariba, Loibl, Sibylle, Mehta, Keyur, Minckwitz, Gunther von, Mundhenke, Christoph, Müller, Berit, Park, Hyerim, Schem, Christian, Thomssen, Christoph, Weimer, Joerg, Wenners, Antonia Sophie   +18 more
core   +14 more sources

Impact on CD4+ CD25High-CD127low regulatory T (Treg) cells of neoadjuvant therapy for rectal cancer patients

Indian Journal of Pathology and Microbiology, 2023
Background: The efficacy of neoadjuvant therapy for rectal cancer has not been assessed. Objective: To evaluate proportional changes in peripheral blood immune cells in rectal cancer patients after neoadjuvant therapy and assess the relationship between ...
Liu Maoxi, Liu Haiyi
doaj   +1 more source

Retrospective review of total neoadjuvant therapy [PDF]

World Journal of Gastrointestinal Oncology, 2019
Neoadjuvant chemoradiotherapy (nCRT) followed by resection and postoperative multi-agent chemotherapy (maChT) is the standard of care for locally advanced rectal cancer. Using this approach, maChT administration can be delayed for several months, leading to concern for distant metastases.
Babar, Laila, Bakalov, Veli, Abel, Stephen, Ashraf, Obaid, Finley, Gene Grant, Raj, Moses S, Lundeen, Kristina, Monga, Dulabh K, Kirichenko, Alexander V, Wegner, Rodney E   +9 more
openaire   +2 more sources

Short-Course or Total Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer - Current Status and Future Perspectives

Frontiers in Surgery, 2022
Neoadjuvant therapy improves overall survival compared with a surgery-first approach in patients with borderline resectable pancreatic cancer (BRPC). Evidence of higher quality is required to determine whether neoadjuvant therapy has potential benefits ...
Knut Jørgen Labori, Knut Jørgen Labori
doaj   +1 more source

Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer

Frontiers in Immunology, 2023
ObjectivesRecent clinical studies have demonstrated that immunotherapy-based neoadjuvant therapy have promising effectiveness for patients with resectable non-small cell lung cancer (NSCLC) in terms of pathologic response.
Jie Shen, Linping Gu, Yuwen Qi, Yaxian Yao, Shun Lu, Zhiwei Chen   +5 more
doaj   +1 more source

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer [PDF]

, 2015
Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC).
Ades, F, Ahmed, R, Asher, R, Beresford, M, De Azambuja, E, Gojis, O, Howell, SJ, Januszewski, A, Lewanski, C, Lythgoe, D, Macpherson, IRJ, Owadally, W, Palmieri, C, Riddle, P, Shah, D, Stanley, B, Yan, K   +16 more
core   +4 more sources

Neoadjuvant Four-Drug Combination Therapy for NSCLC With EGFR Mutation Avoiding Total Pneumonectomy

Frontiers in Oncology, 2020
We report a case of successful neoadjuvant four-drug combination therapy to avoid total pneumonectomy. A 33-year-old male patient was diagnosed with locally advanced non-squamous NSCLC harboring EGFR mutation in the left lower lobe.
Jingpei Li, Jingpei Li, Jingpei Li, Ke Xu, Ke Xu, Ke Xu, Weipeng Cai, Weipeng Cai, Weipeng Cai, Yalei Zhang, Yalei Zhang, Yalei Zhang, Xin Zeng, Fei Cui, Fei Cui, Fei Cui, Zhexue Hao, Zhexue Hao, Zhexue Hao, Jun Liu, Jun Liu, Jun Liu, Jianxing He, Jianxing He, Jianxing He   +24 more
doaj   +1 more source

Bayesian network meta-analysis of efficacy and safety of neoadjuvant therapy for non-small-cell lung cancer

Therapeutic Advances in Medical Oncology, 2020
Objective: Neoadjuvant chemotherapy has increased the survival benefit of non-small cell lung cancer (NSCLC) patients. The effects of different neoadjuvant therapies are still controversial. We carried out the study to evaluate the efficacy and safety of
Yijiu Ren, Hai Tang, Jie Zhang, Yunlang She, Xiaoting Sun, Dong Xie, Chang Chen   +6 more
doaj   +1 more source

Lymph Nodes With Germinal Centers Are Not Associated With Tumor Response After Neoadjuvant Treatment in Locally Advanced Rectal Cancer

Clinical Pathology, 2022
In patients with locally advanced rectal cancer, neoadjuvant radiotherapy or chemoradiotherapy followed by total mesorectal excision as a standard of care. We aimed to explore the number, size, germinal centers, extracapsular invasion of lymph nodes (LN),
Ihsane El Otmani, Boubacar Effared, Fatima El Agy, Mohammed El Abkari, Khalid Mazaz, El Bachir Benjelloun, Abdelmalek Ousadden, Zineb Benbrahim, Touria Bouhafa, Laila Chbani   +9 more
doaj   +1 more source

Neoadjuvant Radiochemotherapy and Total Neoadjuvant Therapy in the Management of Locally Advanced Rectal Cancer. [PDF]

Cureus
Yigit M, Roohani S, Kurreck A, Siegel R, Modest DP, Kaul D, Ehret F.   +6 more
europepmc   +2 more sources